Cryptic Terran Licences Advanced CNS Assets From Sanofi
Deal Value Under Wraps
The US biotech has nabbed a couple of Sanofi’s Phase III CNS candidates, its third deal of the year aimed at transforming the neuropsychiatry market.
You may also be interested in...
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
The major’s atopic dermatitis blockbuster made more than €1.6bn this quarter, but the firm’s R&D costs are rising as it attempts to add some fresh blood to its stagnating pipeline.
Looking to catch up with leaders in in the field of next-generation antibodies, Sanofi has struck a deal with IGM Biosciences for three cancer and three auto-immune/inflammation IgM candidates that hold the promise of greater efficacy.